Trevi Therapeutics Seeks $150 Million in Public Offering
Event summary
- Trevi Therapeutics has announced a proposed public offering of $150 million in common stock.
- The underwriters have an option to purchase an additional $22.5 million worth of shares.
- Morgan Stanley, Leerink Partners, Cantor, Stifel, and Oppenheimer & Co. are acting as advisors for the offering.
- The offering is being made under a shelf registration statement filed with the SEC on November 13, 2025.
- Haduvio™ (oral nalbuphine ER) is Trevi's investigational therapy for chronic cough.
The big picture
This offering suggests Trevi is seeking to bolster its financial position to support the development and potential commercialization of Haduvio, its lead drug candidate. The size of the offering ($150 million) indicates a significant capital need, likely driven by the costs associated with late-stage clinical trials and potential regulatory approval. The reliance on a shelf registration suggests a desire for flexibility and speed in accessing capital markets.
What we're watching
- Market Conditions
- The success of the offering hinges on prevailing market conditions, which have been volatile; a failure to execute at the proposed terms would signal investor skepticism about Trevi's valuation or pipeline.
- Pipeline Progress
- How quickly Trevi can advance Haduvio through clinical trials and regulatory review will dictate the long-term value proposition for investors, particularly given the competitive landscape in cough therapies.
- Capital Needs
- The proceeds from this offering will likely fund ongoing clinical trials and commercialization efforts; the burn rate and efficiency of capital deployment will be critical to maintaining financial stability.
Related topics